Association of CYP7B1 expression with the prognosis of endometrial cancer: a retrospective study.

Humans Female Endometrial Neoplasms / pathology Middle Aged Prognosis Retrospective Studies Biomarkers, Tumor / metabolism Follow-Up Studies Survival Rate Cytochrome P450 Family 7 / metabolism Neoplasm Recurrence, Local / metabolism Adult Neoplasm Staging Receptors, Estrogen / metabolism Receptors, Progesterone / metabolism Aged Steroid Hydroxylases
CYP7B1 Endometrial cancer Estrogen receptor Overall survival

Journal

World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544

Informations de publication

Date de publication:
17 Sep 2024
Historique:
received: 09 02 2024
accepted: 13 08 2024
medline: 18 9 2024
pubmed: 18 9 2024
entrez: 17 9 2024
Statut: epublish

Résumé

Endometrial cancer (EC) tissues express CYP7B1, but its association with prognosis needs to be investigated. Immunohistochemistry and image analysis software were used to assess CYP7B1 protein expression in paraffin-embedded endometrial tumor sections. Associations between CYP7B1 and clinical factors were tested with the Wilcoxon rank-sum test. Kaplan-Meier curves were employed to describe survival, and differences were assessed using the log-rank test. Cox regression analysis was used to assess the association between CYP7B1 expression and the prognosis of patients with EC. A total of 307 patients were enrolled with an average age of 52.6 ± 8.0 years at diagnosis. During the period of follow-up, 46 patients (15.0%) died, and 29 (9.4%) suffered recurrence. The expression of CYP7B1 protein is significantly higher in the cytoplasm than in the nucleus (P < 0.001). Patients aged < 55 years (P = 0.040), ER-positive patients (P = 0.028) and PR-positive patients (P < 0.001) report higher levels of CYP7B1 protein. Both univariate (HR = 0.41, 95% CI: 0.18-0.90, P = 0.025) and multivariate (HR = 0.35, 95%CI:0.16-0.79, P = 0.011) Cox regression analyses demonstrate that high CYP7B1 protein expression predicts longer overall survival (OS). When considering only ER-positive patients (n = 265), CYP7B1 protein expression is more strongly associated with OS (HR = 0.20,95%CI:0.08-0.52, P = 0.001). The 3-year OS and 5-year OS in the low-CYP7B1 subgroup are 81.6% and 76.8%, respectively; while in the high-CYP7B1 subgroup are 93.0% and 92.0%, respectively (P = 0.021). High CYP7B1 protein expression predicted longer OS, suggesting that it may serve as an important molecular marker for EC prognosis.

Sections du résumé

BACKGROUND BACKGROUND
Endometrial cancer (EC) tissues express CYP7B1, but its association with prognosis needs to be investigated.
METHODS METHODS
Immunohistochemistry and image analysis software were used to assess CYP7B1 protein expression in paraffin-embedded endometrial tumor sections. Associations between CYP7B1 and clinical factors were tested with the Wilcoxon rank-sum test. Kaplan-Meier curves were employed to describe survival, and differences were assessed using the log-rank test. Cox regression analysis was used to assess the association between CYP7B1 expression and the prognosis of patients with EC.
RESULTS RESULTS
A total of 307 patients were enrolled with an average age of 52.6 ± 8.0 years at diagnosis. During the period of follow-up, 46 patients (15.0%) died, and 29 (9.4%) suffered recurrence. The expression of CYP7B1 protein is significantly higher in the cytoplasm than in the nucleus (P < 0.001). Patients aged < 55 years (P = 0.040), ER-positive patients (P = 0.028) and PR-positive patients (P < 0.001) report higher levels of CYP7B1 protein. Both univariate (HR = 0.41, 95% CI: 0.18-0.90, P = 0.025) and multivariate (HR = 0.35, 95%CI:0.16-0.79, P = 0.011) Cox regression analyses demonstrate that high CYP7B1 protein expression predicts longer overall survival (OS). When considering only ER-positive patients (n = 265), CYP7B1 protein expression is more strongly associated with OS (HR = 0.20,95%CI:0.08-0.52, P = 0.001). The 3-year OS and 5-year OS in the low-CYP7B1 subgroup are 81.6% and 76.8%, respectively; while in the high-CYP7B1 subgroup are 93.0% and 92.0%, respectively (P = 0.021).
CONCLUSIONS CONCLUSIONS
High CYP7B1 protein expression predicted longer OS, suggesting that it may serve as an important molecular marker for EC prognosis.

Identifiants

DOI: 10.1186/s12957-024-03504-4 PMID: 39289693
pubmed: 39289693
doi: 10.1186/s12957-024-03504-4
pii: 10.1186/s12957-024-03504-4
doi:

Substances chimiques

Biomarkers, Tumor 0
CYP7B1 protein, human EC 1.14.14.29
Cytochrome P450 Family 7 EC 1.14.14.23
Receptors, Estrogen 0
Receptors, Progesterone 0
Steroid Hydroxylases EC 1.14.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

251

Subventions

Organisme : National Natural Science Foundation of China
ID : 82003522

Informations de copyright

© 2024. The Author(s).

Références

Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
pubmed: 33538338 doi: 10.3322/caac.21660
Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860–77.
pubmed: 35690222 doi: 10.1016/j.annonc.2022.05.009
De Felice F, Marchetti C, Tombolini V, Panici PB. Immune check-point in endometrial cancer. Int J Clin Oncol. 2019;24(8):910–6.
pubmed: 31049759 doi: 10.1007/s10147-019-01437-7
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in Endometrial Cancer Risk, Prevention, and treatment. J Clin Oncol. 2016;34(35):4225–30.
pubmed: 27903150 pmcid: 5455320 doi: 10.1200/JCO.2016.69.4638
Gong TT, Li D, Wu QJ, Wang YZ. Cholesterol consumption and risk of endometrial cancer: a systematic review and dose-response meta-analysis of observational studies. Oncotarget. 2016;7(13):16996–7008.
pubmed: 26959738 pmcid: 4941366 doi: 10.18632/oncotarget.7913
Biel RK, Csizmadi I, Cook LS, Courneya KS, Magliocco AM, Friedenreich CM. Risk of endometrial cancer in relation to individual nutrients from diet and supplements. Public Health Nutr. 2011;14(11):1948–60.
pubmed: 21752313 doi: 10.1017/S1368980011001066
Miettinen TA. Cholesterol production in obesity. Circulation. 1971;44(5):842–50.
pubmed: 5115077 doi: 10.1161/01.CIR.44.5.842
Mc Auley MT. Effects of obesity on cholesterol metabolism and its implications for healthy ageing. Nutr Res Rev. 2020;33(1):121–33.
pubmed: 31983354 doi: 10.1017/S0954422419000258
Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89(6):2583–9.
pubmed: 15181027 doi: 10.1210/jc.2004-0535
Feingold KR. Obesity and dyslipidemia. [Updated 2023 Jun 19]. In: Feingold KR, Anawalt B, Blackman MR, et al. editors. Endotext [Internet]. South Dartmouth (MA). MDText.com, Inc.; 2000-.
Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med Clin North Am. 2011;95(5):893–902.
pubmed: 21855698 doi: 10.1016/j.mcna.2011.06.003
Karuna R, Holleboom AG, Motazacker MM, et al. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis. 2011;214(2):448–55.
pubmed: 21130455 doi: 10.1016/j.atherosclerosis.2010.10.042
DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 2008;22(1):65–77.
pubmed: 17872378 doi: 10.1210/me.2007-0383
Gibson DA, Collins F, Cousins FL, Esnal Zufiaurre A, Saunders PTK. The impact of 27-hydroxycholesterol on endometrial cancer proliferation. Endocr Relat Cancer. 2018;25(4):381–91.
pubmed: 29371332 pmcid: 5847183 doi: 10.1530/ERC-17-0449
Abdalkareem Jasim S, Kzar HH, Haider Hamad M, et al. The emerging role of 27-hydroxycholesterol in cancer development and progression: an update. Int Immunopharmacol. 2022;110:109074.
pubmed: 35978522 doi: 10.1016/j.intimp.2022.109074
Starkey NJE, Li Y, Drenkhahn-Weinaug SK, Liu J, Lubahn DB. 27-Hydroxycholesterol is an estrogen receptor β-Selective negative allosteric modifier of 17β-Estradiol binding. Endocrinology. 2018;159(5):1972–81.
pubmed: 29579190 pmcid: 6693046 doi: 10.1210/en.2018-00081
Wu Z, Martin KO, Javitt NB, Chiang JY. Structure and functions of human oxysterol 7alpha-hydroxylase cDNAs and gene CYP7B1. J Lipid Res. 1999;40(12):2195–203.
pubmed: 10588945 doi: 10.1016/S0022-2275(20)32094-0
Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094–8.
pubmed: 24288332 pmcid: 3899689 doi: 10.1126/science.1241908
Wu Q, Ishikawa T, Sirianni R, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 2013;5(3):637–45.
pubmed: 24210818 pmcid: 3950897 doi: 10.1016/j.celrep.2013.10.006
He S, Ma L, Baek AE, et al. Host CYP27A1 expression is essential for ovarian cancer progression. Endocr Relat Cancer. 2019;26(7):659–75.
pubmed: 31048561 pmcid: 6824983 doi: 10.1530/ERC-18-0572
Wang P, Yuan D, Zhang C, et al. High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort. Cardiovasc Diabetol. 2022;21(1):46.
pubmed: 35313877 pmcid: 8939137 doi: 10.1186/s12933-022-01477-w
Rodriguez AC, Blanchard Z, Maurer KA, Gertz J. Estrogen Signaling in Endometrial Cancer: a key oncogenic pathway with several open questions. Horm Cancer. 2019;10(2–3):51–63.
pubmed: 30712080 pmcid: 6542701 doi: 10.1007/s12672-019-0358-9
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014;6:429–35.
pubmed: 24833920 pmcid: 4014387
Chlebowski RT, Anderson GL, Sarto GE et al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women’s Health Initiative Randomized Trial. J Natl Cancer Inst 2016;108(3).
Dallal CM, Lacey JV Jr., Pfeiffer RM, et al. Estrogen Metabolism and risk of postmenopausal endometrial and ovarian Cancer: the B ∼ FIT cohort. Horm Cancer. 2016;7(1):49–64.
pubmed: 26728471 pmcid: 8900527 doi: 10.1007/s12672-015-0237-y
Shi SZ, Lee EJ, Lin YJ, et al. Recruitment of monocytes and epigenetic silencing of intratumoral CYP7B1 primarily contribute to the accumulation of 27-hydroxycholesterol in breast cancer. Am J Cancer Res. 2019;9(10):2194–208.
pubmed: 31720082 pmcid: 6834472
Tan X, Liu S, Yao L, Cui G, Liu J, Ding J. Comprehensive Analysis of a novel lipid metabolism-related gene signature for Predicting the Prognosis and Immune Landscape in Uterine Corpus Endometrial Carcinoma. J Oncol. 2022;2022:8028825.
pubmed: 35190739 pmcid: 8858058 doi: 10.1155/2022/8028825
Le Cornet C, Walter B, Sookthai D, et al. Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort. Breast Cancer Res. 2020;22(1):23.
pubmed: 32075687 pmcid: 7031866 doi: 10.1186/s13058-020-1253-6
Burkard I, von Eckardstein A, Waeber G, Vollenweider P, Rentsch KM. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis. 2007;194(1):71–8.
pubmed: 17107679 doi: 10.1016/j.atherosclerosis.2006.09.026
Kimbung S, Chang CY, Bendahl PO, et al. Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer. Endocr Relat Cancer. 2017;24(7):339–49.
pubmed: 28442559 doi: 10.1530/ERC-16-0533
Raza S, Meyer M, Goodyear C, Hammer KDP, Guo B, Ghribi O. The cholesterol metabolite 27-hydroxycholesterol stimulates cell proliferation via ERβ in prostate cancer cells. Cancer Cell Int. 2017;17:52.
pubmed: 28503095 pmcid: 5425984 doi: 10.1186/s12935-017-0422-x
Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558–68.
pubmed: 15466970 doi: 10.1158/1055-9965.1558.13.10
Siegfried JM, Hershberger PA, Stabile LP. Estrogen receptor signaling in lung cancer. Semin Oncol. 2009;36(6):524–31.
pubmed: 19995644 pmcid: 2818861 doi: 10.1053/j.seminoncol.2009.10.004
Liu J, Sareddy GR, Zhou M, et al. Differential effects of Estrogen Receptor β isoforms on Glioblastoma Progression. Cancer Res. 2018;78(12):3176–89.
pubmed: 29661831 pmcid: 6004261 doi: 10.1158/0008-5472.CAN-17-3470
Van Weelden WJ, Reijnen C, Küsters-Vandevelde HVN, et al. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Hum Pathol. 2021;109:80–91.
pubmed: 33338506 doi: 10.1016/j.humpath.2020.12.003
Ren S, Wu J, Yin W, et al. Researches on the correlation between estrogen and progesterone receptors expression and disease-free survival of Endometrial Cancer. Cancer Manag Res. 2020;12:12635–47.
pubmed: 33335423 pmcid: 7737816 doi: 10.2147/CMAR.S263219
Smith D, Stewart CJR, Clarke EM, et al. ER and PR expression and survival after endometrial cancer. Gynecol Oncol. 2018;148(2):258–66.
pubmed: 29217139 doi: 10.1016/j.ygyno.2017.11.027
Backes FJ, Walker CJ, Goodfellow PJ, et al. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecol Oncol. 2016;141(2):312–7.
pubmed: 26957478 pmcid: 4878441 doi: 10.1016/j.ygyno.2016.03.006
Shin YA, Lee KY. Low estrogen levels and obesity are associated with shorter telomere lengths in pre- and postmenopausal women. J Exerc Rehabil. 2016;12(3):238–46.
pubmed: 27419121 pmcid: 4934970 doi: 10.12965/jer.1632584.292
Yamamoto Y, Moore R, Hess HA, et al. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J Biol Chem. 2006;281(24):16625–31.
pubmed: 16606610 doi: 10.1074/jbc.M602723200
Tang W, Pettersson H, Norlin M. Involvement of the PI3K/Akt pathway in estrogen-mediated regulation of human CYP7B1: identification of CYP7B1 as a novel target for PI3K/Akt and MAPK signalling. J Steroid Biochem Mol Biol. 2008;112(1–3):63–73.
pubmed: 18790053 doi: 10.1016/j.jsbmb.2008.08.004
Tang W, Eggertsen G, Chiang JY, Norlin M. Estrogen-mediated regulation of CYP7B1: a possible role for controlling DHEA levels in human tissues. J Steroid Biochem Mol Biol. 2006;100(1–3):42–51.
pubmed: 16720094 doi: 10.1016/j.jsbmb.2006.02.005
Olsson M, Gustafsson O, Skogastierna C, et al. Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma. Prostate. 2007;67(13):1439–46.
pubmed: 17639508 doi: 10.1002/pros.20630

Auteurs

Xiao-Fang Lu (XF)

Department of Epidemiology, School of Medicine, Jinan University, No. 601, Huangpu Avenue West, Tianhe District, Guangzhou, 510632, China.

Tao Huang (T)

Department of Gynecology, Wuzhou Red Cross Hospital, No. 3-1, Xinxing 1st Road, Wanxiu District, Wuzhou, 543002, China.

Chang Chen (C)

Department of Pathology, Wuzhou Red Cross Hospital, Wuzhou, China.

Jing Zhang (J)

Department of Epidemiology, School of Medicine, Jinan University, No. 601, Huangpu Avenue West, Tianhe District, Guangzhou, 510632, China.

Xu-Yong Fu (XY)

Department of Epidemiology, School of Medicine, Jinan University, No. 601, Huangpu Avenue West, Tianhe District, Guangzhou, 510632, China.

Bo Cheng (B)

Department of Pathology, Chinese People's Liberation Army Rocket Force Characteristic Medical Center, Beijing, China.

Ya-Yan Zhou (YY)

Department of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.

Jia Lei (J)

Department of Gynecology, Wuzhou Red Cross Hospital, No. 3-1, Xinxing 1st Road, Wanxiu District, Wuzhou, 543002, China. leijia33333@sina.com.

Da-Lin Lu (DL)

Department of Epidemiology, School of Medicine, Jinan University, No. 601, Huangpu Avenue West, Tianhe District, Guangzhou, 510632, China. dalinlu@jnu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Association of CYP7B1 expression with the...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital féminin › Tumeurs de l'utérus › Tumeurs de l'endomètre › Association of CYP7B1 expression with the...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Association of CYP7B1 expression with the...
questionsmedicales.fr › Diagnostic › Pronostic › Association of CYP7B1 expression with the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Association of CYP7B1 expression with the...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Association of CYP7B1 expression with the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Association of CYP7B1 expression with the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Association of CYP7B1 expression with the...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Famille-7 de cytochromes P450 › Association of CYP7B1 expression with the...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Association of CYP7B1 expression with the...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Association of CYP7B1 expression with the...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › Association of CYP7B1 expression with the...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Récepteurs aux stéroïdes › Récepteurs des oestrogènes › Association of CYP7B1 expression with the...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs à la progestérone › Association of CYP7B1 expression with the...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Association of CYP7B1 expression with the...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Steroid hydroxylases › Association of CYP7B1 expression with the...